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TuberculosisObjective/background: Despite several studies on health system delay (HSD) among tubercu-
losis (TB) patients in Nigeria, no study has compared HSD in private and public health facil-
ities. This study assessed the determinants of HSD in public and private health facilities
offering the directly observed treatment, short course (DOTS).
Methods: A descriptive cross-sectional study was conducted. A total of 470 new smear-
positive TB patients aged 14 years and older were consecutively recruited between October
1, 2012, and December 31, 2012, from 34 (23 public and 11 private) DOTS facilities that
offered treatment and microscopy services. Mann–Whitney U test and logistic regression
were used to assess the determinants of HSD.
Results: The median HSD was longer at public DOTS facilities (14 days; interquartile range
[IQR] 10–21 days) than private DOTS facilities (12.5 days; IQR 10.0–14.0 days, p = .002). Age
and human immunodeficiency virus status were determinants of HSD at the public DOTS
facilities, whereas sex and income were determinants of HSD at the private DOTS facilities.
TB patients who first visited a nonhospital facility were over four times more likely (odds
ratio 4.12; 95% confidence interval 2.25–7.54) to have prolonged HSD than those who first
visited the government hospital when they first developed the symptoms of TB after con-
trolling for other factors in the model.
Conclusion: Determinants of HSD at the public and private DOTS facilities vary. Strategies to
reduce HSD at both public and private DOTS facilities in Lagos State, Nigeria, are urgently
needed.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).spital, 1-5
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Tuberculosis (TB) remains a serious public health problem in
Nigeria despite the implementation of the directly observed
treatment, short course (DOTS) strategy over two decades
ago [1]. Nigeria ranks fourth among the 22 countries with high
TB burden worldwide [2], with a TB prevalence of 318/100,000
population [1]; however, the country notifies less than one-
fifth of the estimated TB prevalence [3]. Reports from the
2012 TB prevalence survey showed that a majority of TB
patients had not visited a health-care facility; and even if they
did, they were not readily diagnosed as having TB [1]. This
could contribute to continued transmission within the
community.
One of the strategies of the National Tuberculosis and
Leprosy Control Programme aimed at increasing TB case find-
ing by improving access to TB diagnosis and treatment and
reducing delay in accessing care by engaging all private prac-
titioners in the public–privatemix (PPM). This was expected to
link all health-care providers in the private and public sectors
to the National Tuberculosis Programme (NTP) in line with the
STOP TB strategy [4,5]. Despite this effort, health system delay
(HSD) among TB patients in Nigeria was longer than other
high TB-burden countries [6–11], although a systematic
review [12] showed that there was no significant difference
in the mean HSD between low- and middle-income countries
and high-income countries.
According to the World Health Organization determinants
of TB control, risk factors of delayed diagnosis can be divided
into socioeconomic, clinical, and health system factors [13].
Systematic reviews and meta-analysis from developed and
developing countries have demonstrated the determinants
of HSD [14–16]. However, no study to the best of our
knowledge has examined the determinants of HSD at public
and private DOTS facilities. This study therefore assessed
these determinants at public and private DOTS facilities
under the Lagos State TB and Leprosy Control Programme
(LSTBLCP).
Methods
Study design
A descriptive cross-sectional study was conducted to assess
the determinants of HSD at public and private DOTS facilities
in Lagos State, Nigeria.
Study background
Lagos State is located in southwest Nigeria. It is the most
commercialized state of the country. A total of 20 local gov-
ernment areas (LGAs) and 37 local council development areas
were established in the state [17]. Although it is the smallest
state in Nigeria in terms of land mass, with an area of
356,861 ha, of which 75,755 ha are wetlands, it has a popula-
tion of 21 million [17]. The population growth and population
density (2012) of Lagos are about 600,000/year and 4193 per-
sons/km2, respectively. The poverty rate in the state is about64.1% (using dollar/day poverty) and the poverty gap index
is 0.347. The human development index and human poverty
index for the state are 0.607 and 14.5, respectively. Unemploy-
ment rate in Lagos is 19.5%, the Gini coefficient is 0.643, and
the adult literacy rate for male and female is 94% and 85%,
respectively [18,19].
TB control in Lagos State
Health-care services in Lagos State were provided by both
public and private sectors. Of the 2269 registered health-
care facilities in the state in 2012, 1981 (87.3%) were from
the private sector. TB control in Lagos State is coordinated
by the LSTBLCP. The DOTS management of TB started in
Lagos State in 2003 and the PPM for TB management com-
menced in 2008. By 2012, 31 private practitioners had been
engaged in the PPM. Private DOTS providers were engaged
to refer patients suspected of having TB, provide DOTS
treatment, served as an approved microscopy center or
served as both microscopy and treatment center [20].
TB treatment is free in the state; however, patients man-
aged at the private DOTS facilities were charged for consulta-
tion and laboratory test. Those managed at the public DOTS
facilities were also required to pay for any other laboratory
tests other than sputum acid-fast bacilli and GeneXpert.
Treatment duration was 8 months and the treatment regimen
consisted of 2 months’ intensive phase of rifampicin,
isoniazid, pyrazinamide, and ethambutol as fixed-dose
combination and 6 months’ continuation phase of rifampicin
and isoniazid as fixed-dose combination. Patient’s treatment
could either be supervised by health workers at the DOTS
facility or treatment supporter chosen by the patients. To
reduce loss to follow-up, patients diagnosed with TB were
managed at the DOTS facility nearest to their residents.
All presumptive TB clients were offered human immunod-
eficiency virus (HIV) test in accordance with the HIV testing
and counseling policy in the country. Determine (Alere Deter-
mine HIV-1/2 test, Matsuhidai Matsudo-shi, Chiba-ken, Japan)
and Uni-Gold (Trinity Biotech PLC, Wicklow, Ireland) were
used in parallel algorithm. STAT-PAK (Chembio diagnostic
systems Inc., Medford, Newyork, USA) was used as a tie
breaker if a discordant result was obtained. The HIV test
was done free of cost for patients managed at either private
or public DOTS facility. TB/HIV co-infected patients were
offered co-trimoxazole in addition to anti-TB drugs.
Each DOTS facility is managed by a TB focal person who is
responsible for the day-to-day running of the facility and for
ensuring that patient’s records are intact. The records of all
TB patients in DOTS facilities within an LGA are sent to the
state TB program by the LGATB supervisor at the end of every
quarter [21].
Population and sample
From the sampling frame of 130 (99 public and 31) DOTS facil-
ities provided by the Lagos State program officer, all the DOTS
facilities (34 comprising 23 public and 11 private) that served
as both microscopy and treatment centers and that had been
Table 1 – Sociodemographic characteristics of tuberculosis
patients attending selected DOTS facilities in Lagos State,
Nigeria.
Variable Frequency (n = 470), n %
Age group (y)
<35 284 (60.4)
P35 186 (39.6)
Mean ± standard deviation 33.0 ± 11.6
Sex
Male 280 (59.6)
Female 190 (40.4)
Marital status
Married 231 (49.1)
Not marrieda 239 (50.9)
Educational status
No formal education 29 (6.2)
Primary education 84 (17.9)
Secondary 254 (54.0)
Postsecondary 103 (21.9)
Human immunodeficiency virus status
Positive 48 (10.2)
Negative 394 (83.8)
Not done 28 (6.0)
Type of DOTS facility
Public 358 (76.2)
Private 112 (23.8)
Place first visited
Hospital
Private hospital 140 (29.8)
Public hospital 245 (52.1)
Nonhospital
Drug store 25 (5.3)
Self-medication 46 (9.8)
Traditional healers 14 (3.0)
Note: DOTS = directly observed treatment, short course.
a Includes single, divorced, separated, and widowed.
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2 years prior to data collection were recruited into the study.
Newly diagnosed TB patients aged above 14 years having at
least one sputum smear-positive result were consecutively
recruited between October 1, 2012, and December 31, 2012
(last quarter of 2012), from the selected DOTS facilities.
Details of the sample size calculation were published
elsewhere [22].
Study procedure
On recruitment into the study, a structured pretested
interviewer-administered questionnaire was completed by
the patients after they provided written informed consent.
Data relating to places visited after the onset of symptoms,
clinical signs and symptoms and their duration, interval
between onset of symptoms and first visit to the doctor, inter-
val between first visit to the doctor and initiation of treat-
ment, nature of health facility first visited, and whether
treatment was supervised by treatment supporter or by
health worker at the DOTS facilities along with other sociode-
mographic details of patients were obtained. The question-
naire was developed after reviewing relevant literatures and
the NTP’s DOTS worker’s manual [21,23]. Patient interview
was conducted within the 1st week of treatment initiation
to reduce recall bias.
Definition of outcome variable
HSDwas defined in this study as the interval between the first
contact of a presumptive TB patient with a health facility and
the diagnosis of TB [12]. A cutoff of 15 days was used to
indicate prolonged HSD [24].
Data analysis
The Statistical Package of Social Sciences (version 19; IBM,
Armonk, NY, USA) was used for data analysis. Percentages,
median, and interquartile range (IQR) were used to describe
the outcome variable (HSD). Normality of the outcome
variable was assessed using a histogram plot and appropriate
statistical test was used based on the distribution. A chi-
square test was used to compare categorical variables.
Mann–Whitney U test was used to compare median HSD. Bin-
ary logistic regression was used to assess the determinants of
HSD. All (independent) variables that were significant (p < .05)
on bivariate analysis were entered at once (enter method) at
the beginning to assess their predictive ability while control-
ling for the effect of other variables in the model. The quality
of the model was adjudged good when the Omnibus tests of
model coefficients were significant (i.e., p < .05) and the
Hosmer–Lemeshow goodness-of-fit test value was >0.05.
Confidence interval (CI) was set at 95% for all statistical tests.
Statistical test was considered significant if p < .05.
Ethical approval
Ethical approval was obtained from the Health Research and
Ethical Committee of the Lagos State University TeachingHospital. Written informed consent was obtained from TB
patients before recruitment into the study.
Results
Sociodemographic characteristics and clinical presentation of
TB patients
In this study, 470 smear-positive TB patients were recruited.
The mean age of these patients was 33.0 ± 11.6 years. Of
these, 285 patients (60.4%) were less than 35 years of age,
280 (59.6%) were males, and 231 (49.1%) were married. Forty-
eight patients (10.2%) had TB/HIV co-infection; 358 (76.2%)
were treated at the public DOTS facilities, and the remaining
112 (23.8%) were treated at the private DOTS facilities. As
much as 140 (30%) and 245 (52.1%) TB patients visited the
private and public hospitals, respectively, when they first
developed symptoms of TB. Others either went to the drug
store (5.3%), traditional healers (3.0%), or did self-medication
(9.8%; Table 1).
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The overall median HSD of TB patients managed at both pub-
lic and private DOTS facilities was 14 days (IQR 10–20 days).
However, patients treated at the public health facilities had
significantly longer HSD (14 days; IQR 10–21 days) compared
with those treated at the private DOTS facilities (12.5 days;
IQR 10.0–14.0 days, p = .002). At the public DOTS facilities,
patients aged over 35 years (14 days; IQR 13–21 days) and
TB/HIV co-infected patients had longer HSD (21 days; IQR
14–30 days) compared with those aged less than 35 years
(14.0 days; IQR 9.0–20.3 days) and who were HIV negative
(14 days; IQR 9–20 days; p < .05). At the private DOTS facilities,
females (14.0 days; IQR 11.0–19.5 days) and those with
reported monthly income less than 50,000 naira (US $125)
(13 days; IQR 12–20 days) had longer HSD compared with
males (12.0 days; IQR 8.8–14.0 days) and those with reported
monthly income above 50,000 naira, respectively (p < .05). At
the public and private DOTS facilities, those aged above
35 years, TB/HIV co-infected patients, lower income earners
(<50,000 naira/month), those who had hemoptysis, and those
who either did not attend a health facility or went to a private
hospital had longer HSD (p < .05; Table 2).
Patients’ characteristics associated with HSD
Table 3 shows patients’ characteristics associated with HSD.
Age, DOTS facilities where patients were managed, HIV sta-
tus, income, and place first visited by TB patients when theyTable 2 – Health system delay at private and public DOTS facilit
characteristics.
Variable Public DOTS
Median (d, IQR
Health system delay 14.0 (10.0,21.0
Age group (y)
<35 14.0 (9.0,20.3)
P35 14.0 (13.0,21.0
Sex
Male 14.0 (12.0,21.0
Female 14.0 (9.0,21.0)
Marital status
Married 14.0 (12.0,21.0
Not marrieda 14.0 (9.0,21.0)
Educational status
Below secondary 14.0 (12.0,21.0
At least secondary 14.0 (10.0,21.0
Human immunodeficiency virus status
Positive 21.0 (14.0,30.0
Negative 14.0 (9.0,20.0)
Income
<US $125 14.0 (13.0,19.0
PUS $125 14.0 (7.5,14.0)
Hemoptysis
Yes 14.0 (10.0,21.0
No 14.0 (10.0,21.0
Note: DOTS = directly observed treatment, short course; IQR = interquarti
a Includes single, divorced, separated, and widowed.
* Statistically significant values.first developed symptoms of TB were associated with pro-
longed HSD longer than 14 days (p < .05).
Direct logistic regression was performed to assess the
impact of age, type of DOTS facility, HIV status, health facility
first visited, and income on the likelihood of prolonged HSD.
The full model containing all predictors was statistically sig-
nificant (v26 = 56.74 [N = 441], p < .001). The model as a whole
explained between 27.1% (Cox and Snell R2) and 36.3%
(Nagalkerke R2) of the variance in HSD and correctly classified
74.6% of cases. The strongest determinant of prolonged HSD
was first visit to a nonhospital facility (odds ratio [OR] 4.12;
95% CI 2.52–7.549). TB patients who first visited a nonhospital
facility were over four times likely to have prolonged HSD
than those who first visited government hospital when they
first developed symptoms. Other determinants of prolonged
HSD were treatment at the public DOTS facilities, TB/HIV
co-infection, and lower income. Patient treated at the public
DOTS facilities had twofold chance of having prolonged HSD
(OR 2.086; 95% CI 1.455–3.765) than those managed at private
DOTS facilities. In addition, those with TB/HIV co-infection
(OR 3.134; 95% CI 1.605–6.102) and those who first visited
private hospital when they first developed symptoms of TB
(OR 2.975; 95% CI 1.756–5.039) were three times likely to have
prolonged HSD than HIV-negative patients and those who
first visited public hospital when they first developed symp-
toms of TB. However, those who did not visit any health facil-
ity when they first developed the symptoms of TB (OR 4.123;
95% CI 2.252–7.549) and those who earned less than US $125
monthly (OR 3.852; 95% CI 1.406–10.549) had a fourfold chanceies and its relationship with patients’ sociodemographic
Private DOTS
) p Median (d, IQR) p
) 12.5 (10.0,14.0) .002 *
.017 * .632
12.5 (10.0,14.0)
) 12.5 (7.8,14.0)
.222 .035*
) 12.0 (8.8,14.0)
14.0 (11,19.5)
.322 .632
) 13.0 (8.0,14.0)
12.0 (10.5,14.0)
.391 .635
) 13.0 (10.5,18.5)
) 12.0 (9.0,14.0)
<.001* .830
) 13.0 (12.0,15.0)
13.0 (10.0,14.0)
.100 .009 *
) 13.0 (12.0,21.0)
7.0 (5.0,10.0)
.100 .109
) 13.0 (9.5.0,17.5)
) 12.0 (10.0,14.0)
le range.
Table 4 – Determinants of health system delay longer than 14 d.
Variable B Wald p Adjusted odds ratio 95% confidence interval
Age 0.018 3.58 .071 1.018 0.998–1.038
Private DOTS facility 1.0
Public DOTS facility 0.735 5.949 .015* 2.086 1.155–3.765
TB/HIV negative 1.0
TB/HIV co-infection 1.142 11.1491 .001* 3.134 1.605–6.102
Visit to public hospital 1.0
Visit to private hospital 1.090 16.434 <.001* 2.975 1.756–5.039
Visit to nonhospital 1.417 21.068 <.001* 4.123 2.252–7.549
IncomeP US $125 1.0
Income < US $125 1.348 6.881 .009* 3.852 1.406–10.54
Note: DOTS = directly observed treatment, short course; HIV = human immunodeficiency virus; TB = tuberculosis.
* Statistically significant values.
Table 3 – Factors associated with prolonged health system delay among recruited TB patients.
Variable HSD 6 14 d HSD > 14 d OR 95% confidence interval v2 p
N = 353, % N = 117, %
Total 353 (75.1) 117 (24.9)
Age group (y)
15–34 223 (78.5) 61 (21.5) 1.57 (1.01–2.46) 4.476 .034*
P35 130 (69.9) 56 (30.1)
Mean ± standard deviation 32.3 ± 11.4 35.0 ± 12.3
Sex
Male 214 (76.4) 66 (23.6) 1.19 (0.76–1.86) 0.648 .421
Female 139 (73.2) 51 (26.8)
Marital status
Married 170 (73.6) 61 (26.4) 0.85 (0.55–1.32) 0.556 .456
Not marrieda 183 (76.6) 56 (23.4)
Educational status
Below secondary 81 (71.7) 32 (28.3) 0.79 (0.48–1.31) 0.933 .334
At least secondary 272 (76.2) 85 (23.8)
Type of DOTS facility
Public 259 (72.3) 99 (27.7) 0.50 (0.28–0.90) 6.121 .013*
Private 94 (83.9) 18 (16.1)
Cough
Yes 343 (75.6) 111 (24.4) 1.85 (0.58–5.70) 1.408 .235
No 10 (62.5) 6 (37.5)
Hemoptysis
Yes 61 (73.5) 22 (26.5) 0.90 (0.51–1.60) 0.140 .708
No 292 (75.5) 95 (24.5)
Human immunodeficiency virus status
Positive 28 (58.3) 20 (41.7) 0.43 (0.22–0.84) 6.336 .007*
Negative 301 (76.4) 93 (23.6)
Not knownb 24 (85.7) 4 (14.3)
Incomec
<US $125 305 (73.1) 112 (26.9) 0.29 (0.10–0.78) 7.342 .007*
PUS $125 47 (90.4) 5 (9.6)
Facility first visited
Public hospital 204 (83.3) 41 (16.7) NA 18.751 <.001*
Private hospital 95 (67.9) 45 (32.1)
Nonhospital 54 (63.5) 31 (36.5)
Note: DOTS = directly observed treatment, short course; HSD = health system delay; NA = not applicable; OR = odds ratio; TB = tuberculosis.
a Includes single, divorced, separated, and widowed.
b Not part of the analysis.
c 400 naira to US $1 used.
* Statistically significant values.
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the public hospital when they first developed symptoms of
TB and those who earned above US $125 monthly, respec-
tively, as shown in Table 4.
Discussion
Health-care-seeking behavior of TB patients
A majority of the TB patients in this study visited the public
rather than the private hospital when they first developed
symptoms of TB. This finding is contrary to what was
reported in studies from Nigeria and elsewhere where TB
patients sought health care first at private health facilities
[8,25–27]. Out-of-pocket payment for health-care services is
the major source of health-care financing in Nigeria [28] and
this may explain why a majority of the TB patients in this
study visited the public rather than the private hospital when
they first developed symptoms of TB. TB awareness creation
by the LSTBLCP, introduction of treatment supporters in TB
management, and engagement of community volunteers in
active case finding may be also be responsible for this
behavior.
Median HSD at public and private DOTS facilities
In our study, the overall reported median HSD was 14 days
(IQR 10–20 days) and about 25% of the patients recruited had
HSD of more than 14 days. This finding is low compared with
studies from Nigeria and other low- and middle-income
countries that documented longer time for HSD [12,25,29].
Knowledge of health-care workers and availability of labora-
tory reagents and supplies at the public and private DOTS
facilities may be responsible for this finding. Diagnosis of TB
depends on adequate training of health-care workers and
availability of diagnostic facilities [16], especially in patients
without classical signs and symptoms of TB [30,31]. Although
studies from Nigeria, Pakistan, and India have shown that
private practitioners lacked adequate knowledge of TB
management [32–35], there was no significant difference in
the knowledge of health-care workers at the private and
public facilities engaged in the PPM for DOTS management
in Nigeria [36].
The median HSD at public DOTS facilities was longer than
private DOTS facilities (p = .002) in this study. A higher
proportion of TB patients managed at public DOTS facilities
had HSD more than 14 days (p = .013) and the odds of having
HSD longer than 14 days were two times higher at the public
DOTS facility than the private DOTS facilities (OR 2.1; 95%
CI 1.2–3.8). The higher volume of patients seen at the public
DOTS facilities and the cumbersome bureaucracy, which
characterized public hospitals, may explain this finding. In
addition, because of the low volume of patients at private
DOTS facilities, laboratory reagents and supplies were more
readily available in these facilities than in public DOTS
facilities in Lagos, Nigeria [37]. This implies that TB diagnosis
will be faster at private DOTS facilities. There is also the
possibility that patients retained and treated at the private
DOTS facilities presented with classical signs of TB, whereasthose with nonclassical presentations were referred to sec-
ondary and tertiary health facilities with better diagnostic
equipment and specialized health personnel.
Determinants of HSD at the public and private DOTS facilities
Similar to the findings from previous studies, the first visit to
private and traditional practitioner when the symptoms first
appeared was associated with longer HSD than the first visit
to public health facility in this study [38–40]. Unlike the pri-
vate hospitals, laboratory tests such as sputum acid-fast
bacilli and chest X-ray done in public hospitals are usually
accepted at DOTS facilities. Therefore, patients who visited
public hospital first are more likely to have shorter HSD
because they do not have to repeat some of the laboratory
tests done previously.
At the public DOTS facilities, TB/HIV co-infected patients
and patients older than 35 years had significantly longer
HSD. A systematic review on HSD and a study from Nigeria
reported similar findings [16,29]. Those aged 35 years and
above are likely to be engaged in paid employment and thus
need to obtain permission from their managers. As a result,
they may be unable to make scheduled appointments, which
may increase HSD. In addition, fear of stigma may also
contribute to HSD [39]. The shock experienced by patients
diagnosed with HIV and the time required to come to terms
with the diagnosis may have contributed to the longer HSD
among TB/HIV co-infected patients.
Women managed at private DOTS facilities took longer
time to receive TB treatment than men (p = .035). This is in
keeping with findings from Tanzania, Spain, and Turkey
where women remained untreated for a longer time than
men [41–44], but contrary to what was reported in studies
from Brazil and Nigeria [8,45]. Financial dependence of
women on their spouses and family limits their access to
TB services [46] and may be responsible for this finding.
Lower monthly income (<US $125) was a predictor of HSD
more than 14 days in this study. TB patients with lower
income had about fourfold chance of having HSD longer than
14 days (OR 3.85; 95% CI 1.41–10.55) than patients with rela-
tively higher income. At the private DOTS facilities, lower
income earners took longer time to commence TB treatment
than higher income earners (p = .009). Private health-care
facilities, unlike the public facilities, are profit driven;
although TB drugs are given to patients free of cost in the
LSTBLCP, they have to pay for laboratory test. In addition,
inability to pay for laboratory test has been shown to delay
treatment [47–49].
Limitations
This study relied on patient recall, however, data were col-
lected as soon as the patient was enrolled on treatment to
minimize recall bias. Patients who were managed at private
DOTS facilities may differ significantly in certain characteris-
tics from those managed at public DOTS facilities and this
may constitute potential bias in this study. This may be
resolved by randomization of patients into private and public
DOTS providers. However, the study was designed to assess
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under programmatic conditions.
Conclusion
Determinants of HSD at the public and private DOTS facilities
vary. There is a need to address all social, economic, and
bureaucratic issues responsible for prolonged HSD at the
public and private DOTS facilities of the LSTBLCP in Nigeria.
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